Functional Research of Emulsifiers in Humans

ID: NCT03440229
Status: Not yet recruiting
Phase: N/A
Start Date: February 01, 2018
First Submitted: February 05, 2018
Last Updated: February 21, 2018
Results: N/A
Sponsors & Collaborators: University of Pennsylvania, Georgia State University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Location: N/A
Conditions: Healthy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Study Description

Brief Summary

A randomized double-blind study of the effect of carboxymethylcellulose (CMC) on stool microbiota composition, microbiota localization, and metabolic parameters in healthy subjects. It includes a 17-day in-patient stay, randomization to an emulsifier-free group or a CMC group with the same diet except baked goods/sorbet with added CMC at 15g/person/day.

Detailed Description

This is a randomized double-blind, controlled feeding experiment examining the effect of CMC on the stool microbiota composition, gene expression, and microbiota localization with respect to the epithelium. In addition, the investigators will assess the impact of CMC exposure in the diet on markers of metabolic syndrome including response to oral glucose tolerance testing and other plasma metabolite measurements.

Sixteen healthy volunteers will be recruited for a 17-day in-patient study. All participants will receive 3 full days of freshly prepared emulsifier-free food to begin the study. This will be called the "washout period". Participants will then be randomized into an "emulsifier-free" arm and a "CMC" arm in a 1:1 ratio.

Both arms will continue the same diet except that the "CMC" arm's brownie and sorbet will have CMC added to achieve a level of 15 gm per person per day consumption. Serial collection of fecal, plasma, urine and mucosal biopsy samples will be performed to investigate the extent to which CMC consumption by humans impacts the gut microbiota and its interaction with the host parameters related to inflammation and metabolism. Participants will have daily urine and stool collections. Sigmoidoscopies and glucose tolerance testing will be completed on day 4 and 17. Blood samples are collected on days 1-5, 8, 10, 12, 15, and 17.
Condition or disease Intervention/treatment Phase

Healthy

Other: Emulsifier-containing diet
Other Names
Carboxymethylcellulose (CMC)
N/A

Tracking Information

First Submitted DateFebruary 05, 2018
Last Update Posted DateFebruary 21, 2018
Anticipated Start DateFebruary 01, 2018
Anticipated Completion DateSeptember 01, 2019
Anticipated Primary Completion DateSeptember 01, 2019
Results First Submitted DateN/A
Received Results Disposit DateN/A

Current Primary Outcome Measures

  • Distance of nearest bacteria to the epithelium [Time Frame: 17 days]

    Measured distance from the epithelium to the nearest bacteria under high powered microscopy

Original Primary Outcome Measures

Not Available

Current Secondary Outcome Measures

  • Change in weight [Time Frame: 17 days]

    Comparison of weight change during the study period

  • Area under glucose concentration curve [Time Frame: Day 17]

    Area under the glucose concentration curves during the oral glucose tolerance test

  • Area under insulin concentration curve [Time Frame: Day 17]

    Area under the insulin concentration curves during the oral glucose tolerance test

  • Satiety [Time Frame: Days 10,11,15, and 16]

    Satiety is measured on a 10cm VAS. The mean value will be compared between the groups.

  • Fecal lipocalin-2 [Time Frame: Day 17]

    Fecal lipocalin-2 by Elisa

Original Secondary Outcome Measures

Not Available

Study Design

Brief TitleFunctional Research of Emulsifiers in Humans
Official TitleFunctional Research of Emulsifiers in Humans
Brief Summary

A randomized double-blind study of the effect of carboxymethylcellulose (CMC) on stool microbiota composition, microbiota localization, and metabolic parameters in healthy subjects. It includes a 17-day in-patient stay, randomization to an emulsifier-free group or a CMC group with the same diet except baked goods/sorbet with added CMC at 15g/person/day.

Detailed Description

This is a randomized double-blind, controlled feeding experiment examining the effect of CMC on the stool microbiota composition, gene expression, and microbiota localization with respect to the epithelium. In addition, the investigators will assess the impact of CMC exposure in the diet on markers of metabolic syndrome including response to oral glucose tolerance testing and other plasma metabolite measurements.

Sixteen healthy volunteers will be recruited for a 17-day in-patient study. All participants will receive 3 full days of freshly prepared emulsifier-free food to begin the study. This will be called the "washout period". Participants will then be randomized into an "emulsifier-free" arm and a "CMC" arm in a 1:1 ratio.

Both arms will continue the same diet except that the "CMC" arm's brownie and sorbet will have CMC added to achieve a level of 15 gm per person per day consumption. Serial collection of fecal, plasma, urine and mucosal biopsy samples will be performed to investigate the extent to which CMC consumption by humans impacts the gut microbiota and its interaction with the host parameters related to inflammation and metabolism. Participants will have daily urine and stool collections. Sigmoidoscopies and glucose tolerance testing will be completed on day 4 and 17. Blood samples are collected on days 1-5, 8, 10, 12, 15, and 17.

Study TypeInterventional
Study PhaseN/A
Estimated Enrollment
16
Allocation
Randomized
Interventional Model
Parallel Assignment
Masking
Quadruple
Primary Purpose
Other
Conditions
Healthy
Target Follow-Up Duration N/A
Biospecimen:
N/A
Sampling MethodN/A
Study PopulationN/A
Intervention
Other: Emulsifier-containing diet

CMC is one of many synthetic dietary emulsifiers that are incorporated into a variety of processed foods. We have recently shown that, in mice, consumption of P80 and CMC, alters microbiota composition, have pro-inflammatory potential and promote microbiota encroachment into the colonic mucosa, low-grade inflammation, and metabolic syndrome. However, it is not known whether these compounds have similar effects in humans. We would like to study these effects in the human gut microbiota.

Other Names
Carboxymethylcellulose (CMC)
Study Groups/Cohorts
Emuslfier-free diet
This is western style diet prepared without any emulsifiers. Emulsifier free brownies and sorbet are provided daily.

Emulsifier-containing diet
This is a western style diet prepared without any emulsifiers with the exception of the CMC that is included in brownies and sorbet that are provided daily.

Study Arms
Experimental Emulsifier-containing diet
This is a western style diet prepared without any emulsifiers with the exception of the CMC that is included in brownies and sorbet that are provided daily.
Other : Emulsifier-containing diet
CMC is one of many synthetic dietary emulsifiers that are incorporated into a variety of processed foods. We have recently shown that, in mice, consumption of P80 and CMC, alters microbiota composition, have pro-inflammatory potential and promote microbiota encroachment into the colonic mucosa, low-grade inflammation, and metabolic syndrome. However, it is not known whether these compounds have similar effects in humans. We would like to study these effects in the human gut microbiota.

Arm Intervention/Treatment
Experimental Emulsifier-containing diet
This is a western style diet prepared without any emulsifiers with the exception of the CMC that is included in brownies and sorbet that are provided daily.
Other : Emulsifier-containing diet

Recruitment Information

Recruitment Status:Not yet recruiting
Enrollment16
Completion DateSeptember 01, 2019
Eligibility Criteria: Inclusion Criteria:
1. Participant is capable of giving informed consent
2. Participant is age 18 to 60 years

Exclusion Criteria:
1. Diagnosis with IBD, celiac disease, or other chronic intestinal disorders.
2. Baseline bowel frequency less than every 2 days or greater than 3 times daily.
3. Current smoker.
4. Body Mass Index (BMI) <18.5 or >35 at screening.
5. A waist circumference greater than 35 inches (89 centimeters) for women and 40 inches (102 centimeters) for men at screening.
6. A diagnosis of diabetes mellitus or baseline HbA1c > 5.7% or a fasting glucose level of greater than 100mg/dL
7. Systolic blood pressure >130 mmHg or diastolic blood pressure >85 mmHg or treated with medications for hypertension at screening.
8. Fasting triglycerides >149 mg/dl or treated with medications for hypertriglyceridemia
9. Fasting HDL cholesterol <40 mg/dl in men or <50 mg/dl in women or treated with medications for hypercholesterolemia
10. Known substance abuse disorder or consumption of illicit drugs or alcohol in the 24 hours prior to admission to the Center for Human Phenomic Science (CHPS).
11. Prior bowel resection surgery other than appendectomy.
12. Contraindication to flexible sigmoidoscopy and biopsies. Patients with suppressed white blood count may be at increased risk of systemic infection following sigmoidoscopy with biopsies. As such, participants with a WBC less than 3,500 or an absolute neutrophil count of less than 1,000 will be excluded. Patients with thrombocytopenia or with a coagulopathy may be at increased risk of bleeding complications after colonoscopic biopsies. As such, patients with a platelet count of less than 100,000 or an INR greater than 1.2 will be excluded from the study.
13. Estimated GFR<60ml/min/1.73m2 based on measured serum creatinine concentration
14. Pregnant and lactating women.
15. Use of antibiotics in the 6 months prior to admission to CHPS.
16. Use of antacids, NSAIDs, or dietary supplements in the week prior to admission to CHPS. For this study, multivitamins will not be considered dietary supplements.
17. Use of laxatives or anti-diarrhea medications in the two weeks prior to admission to CHPS.
18. Use of anticholinergics in the week prior to admission to CHPS.
19. Use of narcotics in the week prior to admission to CHPS.
20. HIV infection, AIDS, or other known conditions resulting in immunosuppression - determined by direct participant query; no formal testing will be done.
21. Allergies or intolerance to the components of the study diets.
22. Participant has experienced diarrhea within the two weeks prior to admission to CHPS. Diarrhea is defined as a change in bowel habits with an increased frequency or loose stools such that the stool could not be lifted with a fork.
23. Refusal to use a medically accepted method of birth control while participating in this study, such as a barrier method, hormonal contraceptives, implanted birth control devices, permanent methods (such as a vasectomy), and/or abstinence.
24. Vegans and Vegetarians.
25. Student or employee of any one of the investigators.
26. Any condition that the investigator feels may limit the volunteer's ability to complete the study protocol.
GenderAll
Age18 Years to 60 Years
Accepts Healthy VolunteersAccepts Healthy Volunteers
Contacts
Listed Location Countries
Not Available

Administrative Information

NCT Number:NCT03440229
Other Study ID Numbers
828422
R21DK115180
Has Data Monitoring CommitteeNo
U.S. FDA-regulated Product Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Device Product Not Approved or Cleared by U.S. FDA: No
IPD Sharing Statement
Not Available
Responsible PartyJames Lewis, University of Pennsylvania
Study Sponsor
University of Pennsylvania
Collaborators
Georgia State University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Principal Investigator
Jim Lewis, MD, MSCE
University of Pennsylvania